Gastric cancer with high risk of intraperitoneal progression: clinical course and current treatments
By:
References
- 1. Siewert JR, Bottcher K, Stein HJ et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449-461.
- 2. Lim L, Michael M, Mann GB, Leong T. Adjuvant therapy in gastric cancer. J Clin Oncol. 2005;23(25):6220-6232.
- 3. Yoo CH, Noh SH, Shin DW et al. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87(2):236-242.
- 4. Nered SN, Klimenkov AA. Surgical treatment of gastric cancer with a high risk of implantation metastasis. Questions Oncology. 2005;51(1):75-80.
- 5. Koga S, Kaibara N, Itsuka Y et al. Prognostic significance of intraperitoneal free cancer cells in gastric cancer patients. J Cancer Res Clin Oncol. 1984;108:236-238.
- 6. Van den Tole P, Van Rossen E, Van Eijck C et al. Reduction of peritoneal trauma by using non surgical gauze leads to less implantation metastases of spilled tumour cells. Ann Surg. 1998;227(2):242-248.
- 7. Chen S, Cai MY, Chen YB et al. Serosa-penetration in human T4aN0M0 gastric carcinoma correlates with worse prognosis after D2 gastrectomy. Chin Med J. 2012;125(6):1158-1162.
- 8. Maekawa S, Saku M, Maehara Y et al. Surgical treatment for advanced gastric cancer. Hepatogastroenterology. 1996;43(7):178-186.
- 9. Arhelger SW. Advances in diagnosis and management of gastric cancer: II. Trends in the management of gastric csncer. CA Cancer J Clin. 1957;7:161-170.
10.3322/canjclin.7.5.161 - 10. Cunningam D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastro-esophageal cancer. N Engl J Med. 2006;355(1):11-20.
- 11. MacDonald JS, Malley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725-730.
- 12. Wu CW, Lo Wu SS, Shen KH et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg. 2003;27(2):153-158.
- 13. Bentrem D, Wilton A, Mazumdar M et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005;12(5):347-353.
10.1245/ASO.2005.03.065 - 14. Saito H, Kuroda H, Matsunaga T et al. Prognostic indicators in node-negative advanced gastric cancer patients. J Surg Oncol. 2010;101(7):622-625.
- 15. Maehara Y, Hasuda S, Koga T et al. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg. 2000;87(3):353-357.
- 16. Marrelli D, Roviello F, de Manzoni G et al. Different patterns of recurrence in gastric cancer depending on Lauren’s histological type: longitudinal study. World J Surg. 2002;26(9):1160-1165.
10.1007/s00268-002-6344-2 - 17. Roviello F, Marrelli D, de Manzoni G et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90(9):1113-1119.
- 18. Li H, Zhang SW, Liu J et al. Review of clinical investigation on recurrence of gastric cancer following curative resection. Chin Med J. 2012;125(8):1479-1495.
- 19. Sobin LH, Gospodarowicz MK, Wittekind Ch, International Union against Cancer. TNM: Classification of malignant tumors, 7th edition, 2009. Chichester, West Sussex, UK, Hoboken NJ: Wiley-Blackwell;2010:310.
- 20. Schwarz RE, Zagala-Nevarez K. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol. 2002;9(4):394-400.
10.1007/BF02573875 - 21. Skoropad VY, Berdov BA. Influence of the morphological structure of stomach cancer on patterns of recurrence and metastasis. Questions Oncology. 2009;55(1):60-65.
- 22. La Torre M, Ferri M, Giovagnoli MR et al. Peritoneal wash cytology in gastric carcinoma. Prognostic significance and therapeutic consequences. Eur J Surg Oncol. 2010;36(10):982-986.
- 23. Nered SN. Surgical and combined treatment of gastric cancer with a high risk of implantation metastasis and resected gastric cancer: Authoref. of thesis on scientific degree dr. med. sciences. Moscow;2004:21 p.
- 24. D’Ugo D, Persiani R, Ojetti V et al. Prediction of lymph node metastasis in gastric cancer. The 8th International gastric cancer congress (IGCC): abstract book. – Krakow (Poland), 2009, 58.
- 25. Bando E, Yonemura Y, Takeshita Y et al. Intraoperative lavage for cytological examination in 1297 patients with gastric carcinoma. Am J Surg. 1999;178(3):256-262.
- 26. Kaibara N, Iitsuka Y, Kimura A et al. Relationship between the area of serosal invasion and prognosis in patients with gastric carcinoma. Cancer. 1987;60(1):136-139.
- 27. Ikeguchi M, Kondou A, Oka A et al. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg. 1995;161:581-586.
- 28. Adachi Y, Yasuda K, Inomata M et al. Pathology and prognosis of gastric carcinoma. Well versus poorly differentiated type. Cancer. 2000;89(7):1418-1424.
- 29. Skoropad VY, Berdov BA. Clinico-morphological parallels in patients with gastric cancer. Questions Oncology. 2009;55(2):165-170.
- 30. Fukagawa T, Katai H, Saka M et al. Significance of lavage cytology in advanced gastric cancer patients. World J Surg. 2010;34(3):563-568.
10.1007/s00268-009-0355-1 - 31. Moriguchi S, Maehara Y, Korenaga D et al. Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol. 1992;1(5):341-346.
- 32. Japanese Gastric Cancer Association: Japanese classification of gastric cancer. – 2nd English ed. Gastric Cancer. 1998;1(1):10-24.
- 33. Nered SN, Klimenkov AA, Stilidi IS. Signet-ring cell gastric cancer: clinical and morphological aspects, the results of surgical treatment and prognosis. Questions Oncology. 2006;52(3):294-300.
- 34. Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24(14): 2188-2196.
- 35. Hermans J, Bonenkamp JJ, Boon MC et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11(8):1441-1447.
- 36. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002;168(11):597-608.
- 37. Sacuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810-1820.
- 38. Fujitani K, Sasako M, Iwasaki Y et al. A phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically respectable type 4 and large type 3 gastric cancer: JCOG 0210. J Clin Oncol. 2007;25:4609 abstract. [2007 ASCO Meeting proceedings (post-meeting edition)].
- 39. Yoshikawa T, Omura K, Kobayashi O et al. A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg Oncol. 2010;36(6):546-551.
10.1016/j.ejso.2010.04.011 - 40. Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology. 2000;58(2):96-107.
10.1159/000012086 - 41. Chua TC. Progress in the combined modality management of peritoneal carcinomatosis. J Surg Oncol. 2010;102(7):728-729.
10.1002/jso.21748 - 42. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc. 1955;159(18):1704-1707.
- 43. Kimura T, Koyama Y. Preventive chemotherapy after radical operations in stomach cancer. Adv Med Oncol. 1979;9:255-268.
- 44. Spratt JS, Adcock RA, Muskovin M et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40(2): 256-260.
- 45. Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol. 1985;12(3):1-6.
- 46. De Roover A, Detroz B, Detry O et al. Adjuvant hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) associated with curative surgery for locally advanced gastric carcinoma. An initial experience. Acta Chir Belg. 2006;106(3):297-301.
- 47. Fujimoto S, Takahashi M, Mutou T et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer. 1999;85(3):529-534.
- 48. Yonemura Y, de Aretxabala X, Fujimura T et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterol. 2001;48(42):1776-1782.
- 49. Kim JY, Rhew CH, Kim KS et al. Controlled clinical trial for the gastric carcinoma patients underwent surgery plus IHCP. The 3th International gastric cancer congress (IGCC): abstract book – Seoul (Korea). 1999;106.
- 50. Xu DZ, Zhan YQ, Sun XW et al. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol. 2004;18:2727-2730.
10.3748/wjg.v10.i18.2727 - 51. Yan TD, Black D, Sugarbaker PH et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for respectable gastric cancer. Ann Surg Oncol. 2007;14(10):2702-2713.
Language: English
Page range: 190 - 194
Submitted on: Oct 27, 2017
Accepted on: Dec 29, 2017
Published on: Mar 9, 2018
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2018 Roman Yarema, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.